Purchase Order 75N95024P00600
Award Date
9/18/24
Potential Completion Date
9/17/25
Potential Value
$25K
Federal Agency
National Institute on Drug Abuse
Awardee
Pharmaron, Inc.
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Louisville, KY 40202, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to Pharmaron, Inc., a global contract research organization (CRO) specializing in preclinical research services for the pharmaceutical and biotechnology industries, as well as government agencies. The contract was awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), and is part of the NIH Bioanalysis Testing Services 2015-2020 master indefinite-delivery, indefinite-quantity (IDIQ) contract. The contract...
This federal contract award was made by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $101,372.00 firm fixed-price delivery order contract is part of the NIH Bioanalysis Testing Services 2015-2020 indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. Under this award, Pharmaron will provide a range of preclinical research services to support NIDA's drug discovery and development initiatives,...
This federal contract award was issued by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The $143,550.00 firm fixed-price delivery order falls under the NIH Bioanalysis Testing Services 2015-2020 contract vehicle, which provides preclinical research services to support drug discovery and development. The contract does not have a set-aside designation. Pharmaron, a minority-owned, for-profit organization...
This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational Sciences...
This federal contract award to Pharmaron, Inc., a Minority Owned Business and For Profit Organization, was issued by the U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS). The contract, valued at $117,930.00, is a Firm Fixed Price Purchase Order to evaluate NNMT inhibitors in metabolic disorders. Pharmaron, a global contract research organization, will conduct various drug development activities...
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. for $24,624.00. The contract is to obtain pharmacokinetic exposure data from mouse PK studies and plasma protein binding assays, which are common preclinical services provided by Pharmaron, a global contract research organization (CRO) specializing in drug discovery and development. This contract...
This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Pharmaron, Inc.'s Phamaron Inc. Division. The contract, valued at $23,040.00, is for a pharmacokinetics assessment of eight novel compounds in mice and rats. Pharmaron is a global contract research organization (CRO) that specializes in preclinical research services, including pharmacokinetics assessments, toxicity...
This is a $78,300.00 firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Pharmaron, Inc., a minority-owned for-profit organization. The contract is for testing compounds for the blockage of cardiac ion channels, which is a critical step in the drug development process. As a global contract research organization (CRO), Pharmaron has extensive expertise in preclinical research services, including...
This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services. The contract is for testing 20 small molecule compounds in rat pharmacokinetic...
This firm fixed-price purchase order contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Heart, Lung, and Blood Institute to Pharmaron, Inc., a minority-owned for-profit contract research organization, to conduct Good Laboratory Practice (GLP) toxicity studies in rats and dogs. The $102,250.00 contract supports the Institute's Investigational New Drug (IND) enablement project, with Pharmaron performing services such as...